In Service of Two Masters

Premium

Back in 2000, researchers led by Pharmacia's Stephen Geis reported on the outcome of a randomized, controlled trial of celecoxib, the COX-2 inhibitor better known as Celebrex. After six months of treatment, patients who took celecoxib had lower incidence of ulcers and other toxic effects compared to those who took ibuprofen or diclofenac, the researchers reported in the Journal of the American Medical Association. However, as letters to JAMA later pointed out, that data appeared to be cherry-picked.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.